Stock picks with research | support | resistance and technical analysis for trading | Day trading | stock investing in the market
day investing picks penny stock trading
Skip Navigation Links
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event

Join Now

Stock Research for Breakout trading

Advertise 2 ۩  Daily market forecast

NEKTAR THERAPEUTICS COM support | resistance | research

Stock : NKTR |   Stock Recommendations : Buy
Sector : Medical Equipment & Supplies |   First resistance : 7.26
Stock Name : NEKTAR THERAPEUTICS COM |   Second resistance : 13.15
Buy Near : 5.53 |   Third resistance : 17.00
StopLoss : 3.64 |   First Support : 3.64
Posted date : 11/2/2008 12:00:00 AM |   Second Support : 2.91

Nektar Therapeutics com (NKTR) given a nice double top breakout on 10/31/08 with good volume. Again many technical indicators also have given a buy signal, with

   rising moving average weekly and daily Stockhastic given a buy signal and ADX also given a buy signal. Nektar Therapeutics com (NKTR) reported positive Phase 1 data for its lead proprietary oncology product candidate, NKTR-102. As per technical indicator analysis this Stock looks good candidate for portfolio investment and also for day trading, Stock investing, trend trading | swing trading. Due to Stock market and economic condition keep tight stop loss on all position. Buy with our first target $7.26 and keep stop loss $3.64

Stock research

Recent News Head Lines
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
(Wed, 22 Sep 2021 15:09:03 +0000)
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
(Tue, 21 Sep 2021 15:02:17 +0000)
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study. The Phase 2 JAVELIN Bladder Medley study will include locally advanced or metastatic urothelial carcinoma (UC) patients. NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid t
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study
(Tue, 21 Sep 2021 13:00:00 +0000)
Nektar Therapeutics (NASDAQ: NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 (IL-15) receptor agonist, in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma (UC) in the Phase II JAVELIN Bladder Medley study.
Director Of Nektar Therapeutics Trades $544.92 Thousand In Company Stock
(Mon, 13 Sep 2021 15:47:42 +0000)
Robert Chess, Director at Nektar Therapeutics (NASDAQ:NKTR), made a large buy and sell of company shares on September 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Robert Chess purchased 18,279 Nektar Therapeutics shares at a price of $13.80 per share for a total of $252,250 on September 9. They then sold their shares on multiple transactions in the open market. They sold at prices ranging from $16.00 to $16.02 to ra
Even after rising 9.3% this past week, Nektar Therapeutics (NASDAQ:NKTR) shareholders are still down 77% over the past three years
(Thu, 02 Sep 2021 16:03:07 +0000)
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big...

Never go against major trend for day trading | breakout stock trading Before to invest learn day trading strategies online stock trading system stock investing tips stock research .

Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006
Chart courtesy of
Breakout Stock trading - Nektar Therapeutics com research | day trading | stock investing

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.